NfH is also not specific for MS and can also be elevated in other neurological conditions; however, the combination of NfH with other biomarkers, such as myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP), has been shown to improve the specificity of biomarker panels for the diagnosis and prognosis of MS. The gene discussed is GFAP; the disease is myeloid sarcoma.